Multicentric Castleman’s disease: a rare case presentation

Authors

DOI:

https://doi.org/10.18203/2349-3291.ijcp20231507

Keywords:

CD, Angiofollicular lymph node hyperplasia, Giant lymph node hyperplasia, Multicentric CD

Abstract

Castleman’s disease (CD), also known as Angiofollicular lymph node hyperplasia, is a rare lymphoproliferative disorder first reported by dr. Benjamin Castleman in 1956. The estimated incidence rate is 5 to 25 per million person-years. Histologically, the CD can be classified as hyaline-vascular type, plasma cell type and mixed type. HHV-8-associated MCD (Multicentric CD) is most commonly diagnosed in HIV-infected or otherwise immunocompromised individuals. Co-occurrence of polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder and skin changes is known as POEMS syndrome. Treatment of iMCD (idiopathic CD) is challenging, and outcomes are poor because of no uniform treatment guidelines. The anti-interleukin-6 monoclonal antibody Siltuximab with or without corticosteroids is the preferred first-line therapy for iMCD.

References

McCarty MJ, Vukelja SJ, Banks PM, Weiss RB. Angiofollicular lymph node hyperplasia (Castleman's disease). Cancer Treatment Reviews. 1995;21(4):291-310.

Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. Clinical behavior of localized and multicentric Castleman’s disease. Ann Intern Med. 1998;128:657-62.

Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29:670-83.

Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS. 2009;4:16-21.

Fajgenbaum DC. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood. 2018;132:2323-30.

Frizzera G. Atypical lymphoproliferative disorders. In: Knowles DM, editor. Neoplastic Hematopathology. 2nd ed. Philadelphia: Lippincott, Williams and Wilkins. 2001;595-621.

Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol. 2018;180:206-16.

Yu LI, Tu M, Cortes J, Xu-Monette ZY, Miranda RN, Zhang J et al. Clinical and pathological characteristics of HIV- and HHV-8-negative castleman disease. Blood. 2017;129:1658-68.

Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman’s disease: a systematic review of 404 published cases. Ann Surg. 2012;255(4):677-84.

Murakami M, Johkoh T, Hayashi S, Ohshima S, Mizuki M, Nakatsuka SI et al. Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan. Mod Rheumatol. 2020;30:843-51.

Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020;135(16):1353-64.

Wang J, Liang LJ, Wang YM, Mei ZY, Liu YZ, Liu LN et al. Analysis of the clinicopathologic features as well as diagnosis and treatment of 59 patients with Castleman disease. Zhonghua xue ye xue za zhi= Zhonghua Xueyexue Zazhi. 2020;41(8):666-70.

Downloads

Published

2023-05-26

Issue

Section

Case Reports